On Friday, the U.S. Judicial Panel on Multidistrict Litigation ordered 55 cases filed against Eli Lilly and Novo Nordisk over Ozempic, Mounjaro and other medications be coordinated into multidistrict litigation.
February 02, 2024 at 06:27 PM
3 minute read
staff reporter
The original version of this story was published on The Legal Intelligencer
A panel decided Friday to send dozens of lawsuits filed over Ozempic and related drugs prescribed for type 2 diabetes, but increasingly used for weight loss, to a federal judge in Philadelphia.
The U.S. Judicial Panel on Multidistrict Litigation rejected arguments from defendants Novo Nordisk and Eli Lilly to send the cases to other venues, such as North Carolina or California. The panel concluded that at least 13 of the 55 lawsuits so far are in the Eastern District of Pennsylvania.
Presented by BigVoodoo
The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.
The National Law Journal honors attorneys & judges who've made a remarkable difference in the legal profession in the D.C. area.
The premier educational and networking event for employee benefits brokers and agents.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Breaking news and trends for law firm and legal departments about the evolving federal regulations in a volatile political climate.
